Biotech company Regeneron to buy bankrupt 23andMe for $256M

Regeneron will acquire 23andMe for $256 million to ensure the DNA-testing company continues operating and protects customer privacy as promised. The deal includes maintaining access to 23andMe's genetic data for Regeneron's medical research, but concerns about consumer privacy have been raised, with regulators urging deletion of genetic data amid the acquisition's uncertainty.